ESTRO 2020 Abstract book

Overview of micro/nanodosimetry and application to particle beams ........................................................................ (Abs. 728) Real time adpative radiotherapy with MRlinac ................................................................................................................ (Abs. 729)

Symposium The latest news on FLASH: ultra-high dose rate radiotherapy ...................................................................................... (Abs. 730-732) Dose accumulation and re-irradiation for thoracic malignancies ................................................................................ (Abs. 733-736) Multimodal approaches to oligometastatic disease: state-of-the-art in NSCLC ......................................................... (Abs. 737-740) Joint Debate ESTRO-ESGO: This house believes that lymph node dissection can be omitted in FIGO stage IB1/2(<4 cm)iN1(imaging) cervical cancer ........................................................................................................................ (Abs. 741-744) Symposium Quo-vadis log file based QA for adaptive radiotherapy? ............................................................................................... (Abs. 745-747) PBT planning: lessons learned ........................................................................................................................................... (Abs. 748-750) Innovations in radiotherapy ............................................................................................................................................... (Abs. 751-753) Ultra-hypofractionation for localised prostate cancer ................................................................................................... (Abs. 754-757) Joint Symposium ESTRO-IASLC: Combined radiotherapy and immunotherapy in NSCLC ....................................................................... (Abs. 758-761) Symposium Current status of radiotherapy for non-malignant disease outside the brain ............................................................ (Abs. 762-765) Joint Symposium ESTRO-ESR: Online MR-guided radiotherapy - Where are we right now? .................................................................... (Abs. 766-769) Debate This house believes that radiomics will improve predictive models in RT ................................................................... (Abs. 770-773) Symposium Tumour tracking – is it worth the effort? ......................................................................................................................... (Abs. 774-777) Particle Therapy - possibilities and limitations ................................................................................................................ (Abs. 778-780) POSTERS Clinical track: Head and Neck ............................................................................................................................................ (Abs. 786-854) Clinical track: CNS ................................................................................................................................................................ (Abs. 855-909) Clinical track: Haematology ............................................................................................................................................... (Abs. 910-924) Clinical track: Breast ............................................................................................................................................................ (Abs. 925-986) Clinical track: Lung .............................................................................................................................................................. (Abs. 988-1033) Clinical track: Upper GI (oesophagus, stomach, pancreas, liver) .................................................................................. (Abs. 1034-1078) Clinical track: Lower GI (colon, rectum, anus) ................................................................................................................. (Abs. 1079-1115) Clinical track: Gynaecological (endometrium, cervix, vagina, vulva) ............................................................................. (Abs. 1116-1148) Clinical track: Prostate ........................................................................................................................................................ (Abs. 1149-1204) Clinical track: Urology-non-prostate ................................................................................................................................. (Abs. 1205-1221) Clinical track: Skin cancer / malignant melanoma .......................................................................................................... (Abs. 1222-1228) Clinical track: Sarcoma ....................................................................................................................................................... (Abs. 1229-1236) Clinical track: Paediatric tumours ..................................................................................................................................... (Abs. 1237-1244) Clinical track: Palliation ...................................................................................................................................................... (Abs. 1245-1262) Clinical track: Elderly ........................................................................................................................................................... (Abs. 1263-1272) Clinical track: Health services research / health economics .......................................................................................... (Abs. 1273-1284) Clinical track: Communication ........................................................................................................................................... (Abs. 1285-1288) Clinical track: Other ............................................................................................................................................................ (Abs. 1289-1305) Physics track: Basic dosimetry and phantom and detector development .................................................................. (Abs. 1306-1335) Physics track: Dose measurement and dose calculation ............................................................................................... (Abs. 1336-1422) Physics track: Radiation protection, secondary tumour induction and low dose ....................................................... (Abs. 1423-1433) Physics track: Treatment plan optimisation: algorithms ............................................................................................... (Abs. 1434-1463)